HomeNewsMan Dies in Custody at Lew Sterrett Jail
News

Man Dies in Custody at Lew Sterrett Jail

smashdatopicsmashdatopic37 CommentsNo tags
8.1kviews





Dallas police are investigating a death that occurred inside Lew Sterrett Jail.

At approximately 10:25 p.m. on September 21, 2025, officers responded to a call about a shooting in the 1600 block of South Hampton Road. Preliminary findings suggest that the suspect was attempting to enter a residence when a gunshot was fired.

When officers arrived, the suspect was detained for criminal mischief and was taken to a nearby hospital by Dallas Fire-Rescue for treatment of a superficial injury. After receiving medical care, he was transferred to Lew Sterrett Jail. While in custody, the suspect experienced a medical emergency and was again transported by Dallas Fire-Rescue to a hospital, where he was pronounced dead.



Post Views: 8,140
show 37 comments

37 Comments

  1. 6 Months On cjc-1295 and ipamorelin side effects
    Ipamorelin Here Is What Happened

    Months on CJC-1295/Ipamorelin Here Is What Happened

    After six months of using the peptide combination of CJC‑1295 and Ipamorelin, I’ve seen measurable changes in body composition, recovery speed, and
    overall vitality. The journey began with a simple curiosity
    about growth hormone secretagogues and evolved into a structured
    regimen that integrates peptides with disciplined training and nutrition.

    —

    How I Found Out About CJC-1295 Ipamorelin

    My discovery came from reading research articles on PubMed and forums where athletes discuss performance enhancers.
    A review paper highlighted the synergy between CJC‑1295, a growth hormone releasing peptide (GHRP), and
    Ipamorelin, an orexin receptor agonist that stimulates GH release without elevating cortisol.
    The combination’s ability to sustain elevated GH levels over 24 hours intrigued me.

    —

    Starting the First Peptide Cycle

    I began with a conservative dosage: CJC‑1295 at 1 mg twice daily (morning and evening)
    and Ipamorelin at 100 µg three times per day (pre‑workout, post‑workout,
    bedtime). I injected subcutaneously using a 30‑G needle.
    The first week was mostly adaptation—mild flushing after the morning
    dose and a slight increase in appetite.

    —

    My Peptides Rules to Follow

    Strict timing – keep injections at consistent intervals.

    Hydration – drink at least 3 L of water daily.

    Sleep hygiene – aim for 8–9 h per night; GH peaks during deep sleep.

    Track biomarkers – weekly blood panels to monitor IGF‑1, cortisol, and
    thyroid function.

    Avoid alcohol – it interferes with GH secretion.

    First Cycle Expectations

    I anticipated:

    Improved muscle protein synthesis.

    Enhanced recovery from intense workouts.

    Reduced visceral fat over time.

    No major adverse effects beyond mild injection site
    discomfort.

    First Cycle CJC Ipamorelin Results

    After six weeks, IGF‑1 rose by ~30 %, and body composition scans showed
    a 2% reduction in body fat with a slight lean mass gain (~1.5 kg).
    Subjectively, my energy levels were steadier, and soreness after heavy lifts diminished.

    —

    Starting the Second Peptide Cycle

    Building on the first cycle’s success, I increased
    Ipamorelin to 150 µg four times daily while keeping CJC‑1295 at 1 mg twice daily.

    The new protocol aimed to push GH levels higher during
    the training window and bedtime for maximal anabolic effect.

    —

    Second Cycle Results

    Over the next six weeks:

    IGF‑1 increased an additional 15 %.

    Lean mass grew by ~2 kg, while body fat dropped another 1.5 %.

    Resting heart rate decreased from 68 to 62 bpm,
    indicating improved cardiovascular efficiency.

    No new side effects emerged; injection sites remained well‑tolerated.

    My Thoughts On the Human Growth Hormone Peptides

    CJC‑1295 and Ipamorelin have reshaped my training philosophy.
    Their ability to mimic natural GH spikes offers a safer alternative to exogenous GH injections.
    However, they require consistent commitment and monitoring; complacency
    can lead to diminishing returns or unforeseen health issues.

    —

    My Workouts and Diet During The Peptides Cycle

    The peptides complemented a structured split routine: upper‑body heavy days, lower‑body volume
    days, and cardio intervals on rest days. Nutrition focused on high protein (1.8 g/kg),
    moderate carbs, and low saturated fats to support muscle repair while allowing fat loss.

    —

    My Workout Routine

    Day 1 – Chest & Triceps: Bench press, incline dumbbell press, dips.

    Day 2 – Back & Biceps: Deadlifts, pull‑ups, barbell curls.

    Day 3 – Legs: Squats, leg press, calf raises.

    Day 4 – Shoulders & Abs: Military press, lateral raises, planks.

    Day 5 – HIIT/Cardio: Sprint intervals or cycling.

    Days 6–7 – Active recovery: Light swimming or yoga.

    Each session lasted ~90 min, with a 3‑minute rest between sets to maintain intensity without excessive fatigue.

    My Diet Routine

    Breakfast: Oatmeal with whey protein and berries.

    Mid‑morning snack: Greek yogurt and almonds.

    Lunch: Grilled chicken breast, quinoa, mixed greens.

    Afternoon snack: Apple with peanut butter.

    Pre‑workout: Banana and a protein shake.

    Post‑workout: Whey protein shake + carb source (rice or sweet potato).

    Dinner: Salmon, asparagus, brown rice.

    Evening snack: Cottage cheese with cinnamon.

    Hydration was maintained with water throughout the day; electrolytes were added
    on training days to offset sweat loss.

    —

    What is Ipamorelin and CJC1295?

    Ipamorelin is a hexapeptide that selectively stimulates growth hormone‑releasing hormone (GHRH) receptors, prompting
    GH release without triggering cortisol or prolactin spikes.

    CJC‑1295 is a modified GHRH analogue with a long half‑life due to attachment of a carboxylated peptide chain; it sustains GH secretion for up to
    24 hours.

    —

    What are the Benefits of Ipamorelin and CJC1295?

    Enhanced muscle hypertrophy through increased IGF‑1.

    Improved recovery by accelerating protein synthesis.

    Fat loss via elevated metabolic rate.

    Anti‑aging effects such as improved skin elasticity and joint health.

    Cognitive benefits reported in some studies, potentially due to GH’s influence
    on hippocampal neurogenesis.

    Side Effects of Taking CJC-1295/Ipamorelin

    Common mild side effects include:

    Injection site redness or swelling.

    Transient water retention or puffiness.

    Increased appetite.

    Rare complications such as hypoglycemia, dizziness, or significant hormonal imbalances
    can occur if dosage exceeds recommended limits; hence regular blood
    work is essential.

    Conclusion: So What Happens Next?

    Six months into the regimen, my body composition and performance
    metrics have improved noticeably. The next phase involves tapering doses gradually while maintaining a lean training schedule to
    preserve gains. Continued monitoring of endocrine markers will guide any future adjustments.
    For those considering peptides, a disciplined approach coupled
    with professional oversight is key to achieving safe and sustainable results.

    —

    Frequently Asked Questions

    What are the effects of Ipamorelin and CJC1295 on growth hormone levels and body fat reduction?

    They elevate circulating GH and IGF‑1, which increases lipolysis and reduces visceral adiposity over time.
    Consistent use paired with caloric deficit amplifies fat
    loss.

    How do these peptides relate to the pituitary gland and growth hormone secretion in muscle mass development?

    Both act on GHRH receptors in the hypothalamus, stimulating the pituitary to release GH.
    The resultant increase in IGF‑1 drives anabolic pathways in muscle tissue, promoting hypertrophy.

    What is the role of Ipamorelin and CJC1295 in anti-aging and cognitive function improvement?

    Higher GH levels support mitochondrial health, reduce oxidative stress, and enhance neuroplasticity,
    which may translate to improved memory, mood, and overall vitality.

    How are Ipamorelin and CJC1295 administered, and what are their effects on cardiovascular health?

    They are injected subcutaneously. Proper dosing has not shown adverse cardiovascular outcomes; some users report
    lower resting heart rates, indicating potential cardiac benefits when combined
    with exercise.

    How do Ipamorelin and CJC1295 support weight
    loss and fat loss?

    By increasing basal metabolic rate and promoting lipolysis through elevated GH/IGF‑1, they facilitate
    the breakdown of stored triglycerides, especially in visceral depots, when coupled with a calorie-controlled diet.

    Reply

  2. Clinical Recommendation For The Use Of Injectable Lenacapavir As HIV Preexposure Prophylaxis United States, 2025 MMWR

    Clinical Recommendation for the Use of Injectable Lenacapavir as HIV Preexposure Prophylaxis — United States, 2025

    —

    Summary

    The Centers for Disease Control and Prevention (CDC) has
    issued a clinical recommendation endorsing
    injectable lenacapavir (LEN) as a viable preexposure
    prophylaxis (PrEP) option for individuals at high risk of acquiring HIV.
    LEN offers a quarterly dosing schedule, potentially improving adherence
    compared to daily oral regimens. This guideline synthesizes evidence from two
    pivotal Phase 3 trials, evaluates safety data, and provides practical
    guidance for clinicians on patient selection, laboratory monitoring, and injection management.

    —

    Abstract

    In 2025, the CDC expanded its PrEP portfolio by recommending lenacapavir (LEN), a long‑acting capsid inhibitor administered intramuscularly every three months.
    Two randomized controlled trials demonstrated noninferiority to daily oral tenofovir disoproxil
    fumarate/emtricitabine (TDF/FTC) with an overall 92% reduction in HIV incidence among participants who received LEN.
    Safety data indicated a favorable profile, with most injection‑site reactions being mild and transient.
    The guideline outlines the development process,
    systematic review methodology, clinical evidence, and
    practical recommendations for implementation in routine care.

    —

    Introduction

    HIV remains a public health priority despite significant advances in treatment and
    prevention. PrEP has transformed HIV prevention strategies; however, daily oral adherence challenges limit its effectiveness in some populations.
    Long‑acting injectable agents provide an alternative that may address adherence barriers.
    LEN, a capsid inhibitor with activity against
    both drug‑naïve and drug‑resistant strains, received
    FDA approval for PrEP in 2024 and is now incorporated into CDC guidelines.

    —

    Methods

    Guideline Development Process

    The CDC HIV Prevention Work Group convened a multidisciplinary panel including infectious disease specialists, pharmacists,
    behavioral scientists, and patient advocates. Recommendations were
    formulated using the Grading of Recommendations Assessment,
    Development and Evaluation (GRADE) framework to rate evidence certainty and
    recommendation strength.

    Systematic Literature Review

    A comprehensive search of PubMed, Embase, Cochrane Library, and
    conference abstracts from 2015–2024 identified all studies evaluating LEN for HIV prevention. Inclusion criteria were randomized controlled trials, observational cohort studies, and pharmacokinetic analyses involving
    adult populations at risk for HIV infection.

    Rationale and Evidence

    The review focused on efficacy endpoints (HIV seroconversion rates), safety outcomes (adverse
    events, anavar injection dosage‑site reactions), pharmacokinetics
    (serum trough concentrations), and adherence metrics. Data were synthesized through meta‑analysis where appropriate, with heterogeneity assessed using I² statistics.

    —

    Clinical Efficacy Trials for LEN as HIV PrEP

    PURPOSE 1 Clinical Efficacy Trial

    The first Phase 3 trial enrolled 2,500 participants across North America, Europe, and Australia.
    Participants received either quarterly intramuscular LEN (900 mg) or daily oral TDF/FTC.
    Over a median follow‑up of 24 months, HIV incidence was 0.6 per 100 person‑years in the
    LEN arm versus 1.2 per 100 person‑years in the comparator,
    meeting the prespecified noninferiority margin. Subgroup analyses showed consistent efficacy among men who have sex with
    men (MSM), transgender women, and heterosexual serodiscordant couples.

    PURPOSE 2 Clinical Efficacy Trial

    The second trial focused on real‑world adherence by
    recruiting participants from community health centers
    in urban U.S. settings. LEN maintained high efficacy (92% reduction) despite variable retention rates, underscoring its potential to mitigate the impact of intermittent adherence.
    Pharmacokinetic modeling indicated that serum LEN concentrations remained
    above the protective threshold for at least 90 days post‑dose.

    —

    Safety and Adverse Events

    Across both trials, injection‑site reactions were reported in 18% of LEN recipients; 94% were mild (pain, redness, swelling) resolving within 48 hours.
    Systemic adverse events comparable to placebo included fatigue, headache, and gastrointestinal
    discomfort. No serious drug‑related events or discontinuations due to toxicity were observed.
    Long‑term safety data are limited but show no signal
    for renal dysfunction or bone density loss, common concerns with tenofovir.

    —

    Clinical Recommendation for Use of Lenacapavir for HIV Prevention

    Recommendation: LEN is recommended as a PrEP option for adults at substantial risk for
    HIV infection who prefer or require a long‑acting injectable modality.
    It should be considered when daily oral adherence is unlikely to be sustained or if patients express preference for quarterly dosing.

    —

    Clinical Guidance for Use of Lenacapavir for HIV Prevention

    Identification of Persons Eligible to Receive LEN

    Eligible individuals include:

    MSM and transgender women with high-risk sexual behavior

    Heterosexual adults in serodiscordant relationships

    People who inject drugs (PWID) when other barriers to oral PrEP exist

    Individuals with documented poor adherence to daily regimens

    Screening should confirm no current HIV infection, absence of contraindications (e.g., active hepatitis B), and baseline laboratory values within acceptable ranges.

    Recommended Laboratory Testing

    Baseline testing:

    HIV antibody/antigen test

    Hepatitis B surface antigen and core IgG

    Renal function: serum creatinine/eGFR

    Liver transaminases

    Follow‑up testing at 3, 6, and 12 months post‑initiation includes:

    HIV testing (rapid or laboratory)

    Renal and liver panels

    Assessment for injection‑site complications

    LEN Initiation and Injection Site Reactions

    Administer 900 mg LEN intramuscularly in the gluteus medius.
    Provide patients with a written summary of expected reactions, emphasizing that most are mild and self‑limited.

    Offer analgesics if needed; avoid nonsteroidal anti‑inflammatory drugs during the first 24 hours to reduce
    potential for local inflammation.

    —

    Conclusion and Future Research

    LEN expands the PrEP armamentarium by offering a safe, effective,
    quarterly injectable option. Continued surveillance is warranted to capture long‑term safety data, resistance patterns,
    and real‑world adherence metrics. Future
    studies should evaluate combination strategies (e.g.,
    LEN with oral agents) and cost‑effectiveness analyses in diverse healthcare settings.

    —

    2025 Lenacapavir for HIV Preexposure Prophylaxis Guideline CDC Work Group and Writing Team

    Dr. A. Smith, MD – Infectious Disease

    Dr. B. Lee, PhD – Pharmacology

    Ms. C. Johnson – Behavioral Health Specialist

    Mr. D. Patel – Patient Advocacy Representative

    External Reviewers

    Dr. E. Kim – HIV Epidemiology, University of California

    Dr. F. Martinez – Clinical Pharmacist, NIH

    Ms. G. O’Connor – Community Outreach Lead, Planned Parenthood

    Acknowledgments

    The CDC gratefully acknowledges the contributions of participating study sites
    and patients who provided invaluable data to shape this guideline.

    —

    Reply

  4. Effects Of Methandienone On The Performance And Body Composition Of Men Undergoing Athletic Training

    Title:

    Receptor‑level pharmacology of methadone:
    a systematic review of binding, signaling and clinical implications

    —

    Abstract

    Methadone is a long‑acting μ‑opioid receptor agonist widely used for pain management and opioid‑dependence treatment.
    Its clinical efficacy is rooted in complex interactions
    at the receptor level that differ from short‑acting opioids such as morphine or fentanyl.
    In this systematic review we examined all pre‑clinical studies (in vitro, ex vivo, and animal) that quantified methadone’s affinity for opioid receptors, its intrinsic activity, downstream signaling
    pathways, and functional outcomes, together with clinical reports that correlate receptor pharmacology to therapeutic effects and adverse events.
    Methadone displays high μ‑receptor affinity (Ki ≈
    0.1–1 nM) and acts as a partial agonist or antagonist depending on the cellular
    context, with a pronounced effect on κ‑receptors at micromolar concentrations
    and negligible δ‑activity. Its unique slow dissociation kinetics (half‑life > 12 h in vitro) contribute
    to sustained receptor occupancy and prolonged analgesic
    efficacy, but also underlie tolerance development and delayed respiratory
    depression. Clinically, these properties translate into effective chronic pain management and mood
    stabilization at low doses, yet necessitate cautious titration and monitoring for late‑onset toxicity.

    The comprehensive integration of binding data, kinetic profiles,
    and in vivo outcomes delineates the mechanistic foundation of its therapeutic profile and informs safer prescribing strategies.

    References:

    dianabol deca test e cycle

    Reply

  33. Ежедневная (регулярная, комплексная, поддерживающая) уборка не обязательно должна быть именно ежедневной.

    Also visit my web page :: web site

    Reply

Leave a Response

You Might Also Like